Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

Legend Biotech (NASDAQ:LEGN) reported 36% growth in third-quarter global net trade sales of its multiple myeloma treatment CARVYKTI, while executives said slower-than-anticipated gains in earlier-line...

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call ↗

November 10, 2026

Via MarketBeat

Performance

52-Week Range 49.2% below 52-week high

19.06

16.2452W Low 37.5052W High

1 Week 21.9% below 1-week high

19.761W Low 24.421W High

Legend Biotech Corporation - American Depositary Shares (LEGN) traded between $16.24 and $37.50 over the past 52 weeks and last traded at $19.06, 49.2% below its 52-week high. Over the past week it ranged between $19.76 and $24.42.

Past 12 Months

-16.3%

+7.1%

-12.7%

-32.6%

-11.4%

-39.7%

1W -$3.71

1M +$1.26

3M -$2.77

6M -$9.20

YTD -$2.45

1Y -$12.53

LEGN was -39.7% over the past year, -32.6% over six months, -11.4% year to date, -16.3% in the last week.

12 Months vs Market

LEGN

-39.7%

DIA

+10.7%

SPY

+11.6%

QQQ

+11.1%

IWM

+16.0%

Over the past 12 months LEGN returned -39.7% versus DIA (Dow) +10.7%, SPY (S&P 500) +11.6%, QQQ (Nasdaq 100) +11.1% and IWM (Russell 2000) +16.0%.

Volume & Liquidity 1.39× 3-mo avg

Today 3,077,809 3-mo avg 2.2M

3.3M

2.3M

2.2M

2.5M

YTD

2.4M

LEGN most recently traded 3,077,809 shares against a 3-month average daily volume of 2.2M.

More News

Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights

November 10, 2026

Gabelli Releases Agenda for 8th Annual Healthcare Symposium

November 09, 2026

From Gabelli Funds

Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026

November 04, 2026

Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results

October 27, 2026

Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

October 15, 2026

Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

October 01, 2026

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

September 25, 2026

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

September 15, 2026

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

September 10, 2026

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

September 01, 2026

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗

August 31, 2026

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript ↗

August 11, 2026

Legend Biotech Q2 Earnings Call Highlights ↗

August 11, 2026

Via MarketBeat

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

August 11, 2026

Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results

July 28, 2026

Legend Biotech Announces CEO Transition

July 27, 2026

2 Biotech Stocks Worth Buying Before Their Potential Buyouts ↗

June 27, 2026

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

June 23, 2026

From Calidi Biotherapeutics, Inc

Legend Biotech Corporation Announces Pricing of Public Offering

June 17, 2026

Legend Biotech Corporation Announces Proposed Public Offering

June 17, 2026

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

June 15, 2026

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

June 14, 2026